Oppenheimer analyst Hartaj Singh is out with a new research note on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), reiterating an Outperform rating and price target …
Yesterday evening, Catabasis Pharmaceuticals Inc (NASDAQ:CATB) announced that lead candidate edasalonexent missed the primary endpoint in its Phase II proof-of-concept trial in Duchenne …
Ocular Therapeutix Inc (NASDAQ:OCUL) shares fell more than 50% on Friday, after the company’s most advanced asset, a sustained-release formulation of the anti-inflammatory dexamethasone (branded as …
BTIG analyst Hartaj Singh weighed in today with a pessimistic view on Keryx Biopharmaceuticals (NASDAQ:KERX), after the company announced that its lead candidate Aurxyia (Fexeric in the …
The first quarter of 2015 has come to a close and companies are still releasing earnings reports. Let’s look back and see which …
BTIG’s healthcare analyst Hartaj Singh came out with a research note on Keryx Biopharmaceuticals (NASDAQ:KERX), after the company reported its fourth-quarter financial results and provided a corporate update. The analyst …
In a research report issued Friday, BTIG analyst Hartaj Singh reiterated a Neutral rating on Keryx Biopharmaceuticals (NASDAQ:KERX), after the company released its full …
